Market Wire - Investment Opinion (Free subscription) | 07/17/2008
WESTON, FL (MARKET WIRE) Wall Street News Alert's "stocks to watch" this morning are: Oncolin Therapeutics (OTCBB: OCOL), Bristol-Myers Squibb Company (NYSE: BMY), Cephalon, Inc. (NASDAQ: CEPH) and Oracle Corporation (NASDAQ: ORCL).
Business Wire (Free subscription) | 07/17/2008
CHICAGO--(BUSINESS WIRE)--Zacks Equity Research highlights Canadian Solar (Nasdaq: CSIQ) as the Bull of the Day and The Corp. Executive Board (Nasdaq: EXBD) as the Bear of the
Medical News Today (Free subscription) | 07/16/2008
Cephalon, Inc. (Nasdaq: CEPH) announced that in a phase 2 study published online in the Journal of Clinical Oncology, 92 percent of patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma (NHL) responded to treatment with TREANDA(R) (bendamustine hydrochloride) for Injection plus rituximab.
ShoeMoney (Free subscription) | 07/15/2008
Techcrunch had a interesting story today about lots Silicon Valley entrepreneurs being hopped up on Provigil. Provigil (aka Modafinil) is marketed by Cephalon in the United States and is available by prescription only. It’s only approved use in the U.S. is to treat narcolepsy, a sleeping disorder. But since the main effect of [...]
PR News Wire (Free subscription) | 07/15/2008
Study Reports 92 Percent Response Rate to Combination Treatment FRAZER, Pa., July 15 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that in a phase 2 study published online today in the Journal of Clinical Oncology, 92 percent of patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma (NHL) responded to treatment with TREANDA(R) (bendamustine hydrochloride)...
Red Orbit (Free subscription) | 06/17/2008
FRAZER, Pa., June 17 /PRNewswire-FirstCall/ -- Cephalon, Inc. announced today that the U.S. Patent and Trademark Office has issued a pharmaceutical formulation patent for AMRIX(R) (Cyclobenzaprine Hydrochloride Extended-Release Capsules). U.S. Patent No.
PR News Wire (Free subscription) | 06/17/2008
FRAZER, Pa., June 17 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the U.S. Patent and Trademark Office has issued a pharmaceutical formulation patent for AMRIX(R) (Cyclobenzaprine Hydrochloride Extended-Release Capsules). U.S. Patent No. 7,387,793 was issued to Eurand Inc., the developer of AMRIX, and expires on February 26, 2025. Last year, Cephalon acquired an exclusive...
RFID Journal (Free subscription) | 06/14/2008
In the latest phase of its RFID deployment, the drugmaker is serializing cardboard shipping containers by means of EPC Gen 2 tags.
Market Wire - Investment Opinion (Free subscription) | 06/11/2008
WESTON, FL (MARKET WIRE) Wall Street News Alert's "stocks to watch" this morning are: MedSpas of America, Inc. (PINKSHEETS: MEDP), Gilead Sciences, Inc. (NASDAQ: GILD), Cephalon, Inc. (NASDAQ: CEPH) and Oracle Corporation (NASDAQ: ORCL).
Patent Docs (Free subscription) | 06/07/2008
By Donald Zuhn -- Last month, we reported on the lobbying expenditures for a number of biotech and pharmaceutical companies in the first quarter of 2008. Included on our list were Cephalon, Inc., which spent $512,000, Abbott Laboratories, which spent $880,000, and Amgen Inc., which spent $2.5 million. That list...
Business Wire (Free subscription) | 06/04/2008
WALTHAM, Mass.--(BUSINESS WIRE)--OATSystems today announced that Cephalon, Inc. has selected OAT
Deseret Morning News (Free subscription) | 06/04/2008
Cephalon Inc. said Tuesday that it has sued Watson Pharmaceuticals Inc. to prevent the generic-drug maker from selling a low-cost copy of the painkiller Fentora.
The Philadelphia Business Journal (Free subscription) | 06/03/2008
Cephalon Inc. and its wholly owned subsidiary Cima Labs Inc. filed a patent infringement lawsuit Tuesday against Watson Laboratories Inc., which wants to make a generic version of Cephalon's Fentora drug for cancer pain. (CEPH) (WPI)
Market Watch (Free subscription) | 06/03/2008
NEW YORK (MarketWatch) -- Pharmaceutical company Cephalon Inc. said Tuesday that it and its Cima Labs subsidiary have filed a lawsuit in U.S. District Court against Watson Pharmaceuticals Inc. and its Watson Laboratories subsidiary for infringement of patents that cover methods of use for its Fentora pain medication. According to the company, the patents in question do not expire until 2019. Watson...
PR News Wire (Free subscription) | 06/03/2008
FRAZER, Pa., June 3 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon...
The last article published by a user on Cephalon :
sunilnair | 12/25/2007
Cephalon Inc.: PharmaVitae Profile Introduction This analysis examines the historical and forecast performance for Cephalon in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated...
